Virtual Symposium on Human Papillomavirus

Virtual Symposium on Human Papillomavirus

Date: February 9, 2026
Format: Virtual
Organizer: IRC – Impact Research Communications

The HPV 2026 symposium convened leading researchers and clinicians to explore the molecular, immunological, and clinical dimensions of human papillomavirus (HPV) and its associated cancers. The one-day program highlighted advances in targeted therapies, immune modulation, diagnostics, and genomic insights—underscoring the global commitment to reducing HPV-related disease burden.

Scientific Highlights

Session I: Molecular Mechanisms & Oncoproteins

  • Dr. Jennifer Binning (USA) presented engineered degraders of the HPV E6 oncoprotein, offering a novel therapeutic strategy to dismantle viral oncogenesis.
  • Dr. Takuya Nakagawa (Japan) discussed extrachromosomal DNA in HPV-associated cancers, revealing its role in tumor evolution and heterogeneity.
  • Dr. Simona Stolnicu (Romania) emphasized HPV status as a critical factor in classifying and prognosing cervical epithelial malignancies.
  • Dr. Yotam Drier (Israel) highlighted MYB overexpression and tumor heterogeneity in HPV-related sinonasal and adenoid cystic carcinomas.

Session II: Immunity, Immune Checkpoints & Genomic Disruption

  • Dr. Jian Zhu (USA) examined immune dysregulation in HPV-associated head and neck cancers, identifying pathways of immune escape.
  • Dr. Khaled Sanber (USA) demonstrated that intratumoral HPV16-reactive CD8+ T cells correlate with response to immune checkpoint blockade, pointing toward predictive biomarkers.
  • Dr. Cristina Montagna (USA) explored genome disruption in HPV-associated lesions, linking structural changes to disease progression.
  • Dr. Subhasis Biswas (USA) connected HPV DNA replication, oncogene transcription, and oncogenesis, offering a systems-level view of viral persistence and malignancy.

Key Takeaways

  • Targeted therapies such as E6 degraders represent a promising frontier in HPV oncology.
  • Genomic insights into extrachromosomal DNA and structural disruption deepen understanding of cancer progression.
  • Immune modulation and checkpoint blockade responses highlight the importance of host-virus interactions.
  • Biomarkers and classification systems are evolving to improve diagnosis, prognosis, and treatment personalization.

Global Participation

The symposium featured speakers from USA, Japan, Romania, Israel, and France, reflecting the international scope of HPV research and collaboration.

Conclusion

The HPV 2026 symposium showcased the convergence of molecular biology, immunology, and clinical innovation in tackling HPV-associated cancers. By advancing targeted therapies, refining diagnostics, and harnessing immune responses, the global research community continues to move closer to reducing the burden of HPV-related disease.